Drugs to combat HIV are about to become cheaper in developing countries. The
multinationals Glaxo Wellcome and Hoffmann-La Roche will supply drugs at cut
rates to Uganda, Côte d’Ivoire, Chile and Vietnam in a two-year pilot
initiative organised by the Joint UN Programme on HIV/AIDS. Virco, a Belgian
diagnostics company, will train local technicians to screen patients to work out
which drugs to use. “We want to demonstrate that it is workable and
sustainable,” says Joseph Saba, the initiative’s coordinator. The extent of the
discounts is still being worked out.
More from New Scientist
Explore the latest news, articles and features
Life
Has the answer to life's origins been hiding in our cells all along?
Features
ÎçÒ¹¸£Àû1000¼¯ºÏ
Sperm have been made magnetic to allow IVF inside the body
News
ÎçÒ¹¸£Àû1000¼¯ºÏ
The social media ban is an experiment – here’s how it will be studied
News
Technology
Inside the start-up aiming for a giant leap in robot intelligence
News
Popular articles
Trending New Scientist articles
1
Has the answer to life's origins been hiding in our cells all along?
2
We may have finally solved cosmology's chicken-or-the-egg problem
3
Fully autonomous drones have killed human soldiers for the first time
4
Sperm have been made magnetic to allow IVF inside the body
5
The relationship recession is even bigger for Gen Z than we thought
6
Vaping after quitting smoking is linked to lung cancer
7
Q-Day could destroy bitcoin – and our retirement savings
8
Toy universe shows that time could be a quantum illusion
9
Mysterious ‘cold blob’ in the Atlantic suggests the AMOC is weakening
10
Pancreatic cancer halted by virus injection in three patients
